Following is one of the patent documents most requested by researchers using CAS electronic products.
|
CAS indexed 170 chemical substances from this document.
CAS subject entries for this document include: Ribonucleic acids; Ribonucleic acids, messenger; Protein formation; and 3 additional concepts. | |
CAPLUS COPYRIGHT 2007 ACS on STN
| TITLE:
| Nuclease-resistant modified oligonucleotide for detecting and modulating RNA activity and gene expression |
| INVENTOR(S):
| Cook, Philip Dan; Ecker, David J.; Guinosso, Charles John; Acevedo, Oscar Leobardo; Kawasaki, Andrew Mamoto; Ramasamy, Kandasamy |
| PATENT ASSIGNEE(S):
| Isis Pharmaceuticals, Inc., USA |
| SOURCE:
| PCT Int. Appl., 194 pp. CODEN: PIXXD2 |
| LANGUAGE:
| English |
PATENT INFORMATION: PATENT NO. KIND DATE APPLICATION NO. DATE
--------------- ---- -------- -------------------- --------
WO 9110671 A1 19910725 WO 1991-US243 19910111
W: AU, BR, CA, FI, HU, JP, KR, NO, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE
CA 2073500 A1 19910712 CA 1991-2073500 19910111
AU 9171798 A 19910805 AU 1991-71798 19910111
AU 651569 B2 19940728
BR 9105935 A 19921117 BR 1991-5935 19910111
JP 05502031 T 19930415 JP 1991-503393 19910111
JP 2580091 B2 19970212
HU 63170 A2 19930728 HU 1992-2283 19910111
EP 604409 A1 19940706 EP 1991-903066 19910111
EP 604409 B1 20040714
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE
EP 1418179 A2 20040512 EP 2003-78862 19910111
EP 1418179 A3 20060308
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE
AT 271064 T 20040715 AT 1991-903066 19910111
CA 2089376 A1 19920214 CA 1991-2089376 19910812
EP 1443051 A2 20040804 EP 2004-76246 19910812
EP 1443051 A3 20050817
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE
AT 318273 T 20060315 AT 1991-915355 19910812
ES 2259177 T3 20060916 ES 1991-915355 19910812
FI 9203176 A 19920709 FI 1992-3176 19920709
NO 9202718 A 19920909 NO 1992-2718 19920709
US 6783931 B1 20040831 US 1993-117363 19930903
US 6060592 A 20000509 US 1994-212006 19940311
US 6153737 A 20001128 US 1994-211882 19940422
US 6358931 B1 20020319 US 1994-295744 19940830
US 6262241 B1 20010717 US 1995-383666 19950203
JP 08098700 A 19960416 JP 1995-175173 19950711
JP 3585583 B2 20041104
US 7037646 B1 20060502 US 1996-602862 19960228
US 6339066 B1 20020115 US 1997-829637 19970331
AU 9726244 A 19971106 AU 1997-26244 19970624
AU 713740 B2 19991209
US 5948903 A 19990907 US 1998-74503 19980508
US 6232463 B1 20010515 US 1998-128508 19980804
US 6239265 B1 20010529 US 1998-208533 19981209
US 6369040 B1 20020409 US 1999-384826 19990827
US 6395492 B1 20020528 US 2000-633659 20000807
US 2001008936 A1 20010719 US 2001-784917 20010216
US 6500945 B2 20021231
US 2002160972 A1 20021031 US 2001-974326 20011010
US 6610663 B2 20030826
US 2003004325 A1 20030102 US 2001-996263 20011128
US 7138517 B2 20061121
US 2003064492 A1 20030403 US 2002-154993 20020523
US 6919439 B2 20050719
US 2003175751 A1 20030918 US 2002-284742 20021031
ABSTRACT:
Oligonucleotide analogs contg. modified sugars are prepd. for use in antisense oligonucleotide diagnostics and therapeutics. Protected 2'-o-nonyladenosine phosphoramidate was prepd. and incorporated by solid phase synthesis into 15-mers complementary to a portion of the papillomavirus genome. The Tm of the unmodified 15-mer and the Tm's of the 15-mers contg. 1 of 3 adenosine analogs were comparable but the nuclease resistance was increased approx. 5- and 64-fold, resp.
Updated 4/24/2007 1:18:16 PM
